Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ubiquitin-conjugating enzyme E2C (UBE2C) is an anaphase-promoting complex/cyclosome (APC/C)-specific ubiquitin conjugating enzyme, which acts as an oncogene in PCa progression.
|
31646760 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConfirmMDx for Prostate Cancer (MDxHealth, Irvine, CA).
|
29660369 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this paper, a CTC detection system for prostate cancer (PCa) was developed on the basis of epithelial cell adhesion molecule (EpCAM)-targeted immunomagnetic separation and CK-FITC and SATB-1-APC immunofluorescence assay, and the recovery rate of tumor cells in PBS and simulated whole blood by this system was detected.
|
31165705 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
In tissue samples, methylation panel #1 and panel #2 detected PCa with AUC of 0.9775 and 1.0, respectively, whereas in urine samples, panel #2 demonstrated superior performance although a combination of miR-34b/c, miR-193b, APC, and RARβ2 disclosed the best results (AUC = 0.9817).
|
30373654 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In White men, methylation of the APC gene was associated with increased risk of BCR, even after adjusting for standard clinical risk factors for prostate cancer progression (adjusted hazard ratio (aHR) = 2.26; 95%CI 1.23-4.16).
|
26860439 |
2016 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Herein, we developed, optimized and standardized a multiplex MethyLight assay to simultaneously detect hypermethylation of APC, HOXD3 and TGFB2 in DNA extracted from prostate cancer (PCa) cell lines, archival tissue specimens, and urine samples.
|
24651255 |
2014 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A multiplex quantitative methylation specific polymerase chain reaction assay determining the methylation status of GSTP1, APC and RASSF1 was strongly associated with repeat biopsy outcome up to 30 months after initial negative biopsy in men with suspicion of prostate cancer.
|
22999998 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
From this study, the results suggest that APC promoter methylation may be the potential testing for PCa diagnosis and provide a new viewpoint in the treatment of PCa.
|
23299921 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
The assay is designed to detect epigenetic modifications in the 3 markers GSTP1, RARβ2 and APC, which are indicative of prostate cancer.
|
21944123 |
2011 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our study demonstrated that quantitative increase in promoter methylation levels of APC, HOXD3 and TGFβ2 are associated with PCa progression.
|
21207416 |
2011 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hypermethylation was more frequent in PCa than in BPH tissues (EDNRB, 100% versus 88%; TIG1, 96% versus 12%; RARbeta, 95% versus 35%; GSTP1, 93% versus 15%; APC, 80% versus 50%; MDR1, 80% versus 31%; PTGS2, 68% versus 15%; Reprimo, 59% versus 19%; and Annexin2, 4% versus 0%).
|
18242387 |
2008 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
CpG island hypermethylation at APC, retinoic acid receptor beta (RAR-beta), and PTGS2 discriminated with a sensitivity of 65-83% and a specificity of 97-100% between BPH and pCA.
|
16956712 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
|
17947477 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
Inactivation of Apc in the mouse prostate causes prostate carcinoma.
|
17363566 |
2007 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We observed a slightly increased risk of prostate cancer in relatives of APC I1307K carriers, however, this difference was not statistically significant (hazard ratio, 1.6; 95% confidence intervals, 0.7-3.4).
|
16537703 |
2006 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that PMA values of APC and RARbeta2 were higher than those of GSTP1 in all three types of tissue samples and median PMA values for all three genes were higher in prostate cancer.
|
16446401 |
2006 |
Malignant neoplasm of prostate
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
At three gene loci (GSTP1, APC, and PTGS1) and CpG island, hypermethylation was highly prevalent in prostate cancers (71-91%), and analysis of receiver operator curves showed that hypermethylation at these three gene loci can distinguish between prostate cancer and noncancerous prostatic tissue (i.e., benign hyperplasia) with a sensitivity of 71.1% to 96.2% and a specificity of 92.9% to 100%.
|
15930345 |
2005 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
We tested urine sediment DNA for aberrant methylation of nine gene promoters (p16INK4a, p14(ARF), MGMT, GSTP1, RARbeta2, CDH1 [E-cadherin], TIMP3, Rassf1A, and APC) from 52 patients with prostate cancer and 21 matched primary tumors by quantitative fluorogenic real-time polymerase chain reaction.
|
16170165 |
2005 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further studies may clarify whether t3 elevation is the mechanism whereby APC gene mutations increase the risk of prostate cancer, or whether other pathophysiologic abnormalities are involved.
|
12856637 |
2003 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.
|
11921277 |
2002 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genes underlying these cancers are now recognized in colorectal cancer (APC, mismatch repair genes, LKB1) and in breast cancer (BRCA1, BRCA2) whereas, in prostate cancer, a locus in chromosome 1 (HPC1) has been proposed on the basis of linkage analysis.
|
9690990 |
1998 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A series of 25 primary prostate cancers in Japanese were screened for loss of heterozygosity and microsatellite instability using twelve microsatellite markers containing APC, DCC, TP53, BRCA1, and BRCA2.
|
9778625 |
1998 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study clarified that APC gene mutations are not largely involved in the development of clinical prostate cancer.
|
8609698 |
1996 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic alterations of ras oncogenes (K-, H- and N-ras) and adenomatous polyposis coli (APC) gene in tissues of prostate cancer from Japanese patients were examined using PCR-SSCP (polymerase chain reaction-single strand conformation polymorphism) analysis and direct sequencing.
|
7928631 |
1994 |